BCAB (BioAtla, Inc. Common Stock) Stock Analysis - Financials

BioAtla, Inc. Common Stock (BCAB) is a publicly traded Healthcare sector company. As of May 21, 2026, BCAB trades at $3.44 with a market cap of $6.50M and a P/E ratio of -0.73. BCAB moved -3.36% today. Year to date, BCAB is -82.97%; over the trailing twelve months it is -81.51%. Its 52-week range spans $3.26 to $126.25. Rallies surfaces BCAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are BCAB's key financials?

BCAB financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BCAB recently traded at $3.44. Market cap is $6.50M. P/E ratio is -0.73. Revenue is $2.00M.

BCAB Key Metrics

Key financial metrics for BCAB
MetricValue
Price$3.44
Market Cap$6.50M
P/E Ratio-0.73
EPS$-4.97
Dividend Yield0.00%
52-Week High$126.25
52-Week Low$3.26
Volume20
Avg Volume0
Revenue (TTM)$2.00M
Net Income$-50.62M
Gross Margin0.00%

BCAB Annual Financials

YearRevenueNet IncomeEPS
2025$2.00M$-59.61M$-1.01
2024$11.00M$-69.78M$-1.44
2023$0$-123.46M$-2.58
2022$0$-106.48M$-2.74

Latest BCAB News

BCAB Analyst Consensus

BCAB analyst coverage data. Average price target: $0.00.

Common questions about BCAB

What are BCAB's key financials?
BCAB financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BCAB recently traded at $3.44. Market cap is $6.50M. P/E ratio is -0.73. Revenue is $2.00M.
Is BCAB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BCAB. It does not provide personalized investment advice.
BCAB

BCAB